Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Opat

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
British Journal of Cancer|July 30, 2014
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaC Y Cheah, K E Herbert, K O'Rourke, et al.
Hematological Oncology|April 16, 2019
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphomaZi Yun Ng, Mark Bishton, David Ritchie, et al.
Internal Medicine Journal|September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statementMary A Anderson, Rory Bennett, Xavier Badoux, et al.
NEJM Evidence|June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's LymphomaAngie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Blood Advances|September 8, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA studyStephen Opat, Alessandra Tedeschi, Bei Hu, et al.
Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
Internal Medicine Journal|July 7, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 updateSean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, et al.
Leukemia|April 23, 2022
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphomaJonathan Wong, Emily Gruber, Belinda Maher, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
British Journal of Cancer|July 30, 2014
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaC Y Cheah, K E Herbert, K O'Rourke, et al.
Hematological Oncology|April 16, 2019
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphomaZi Yun Ng, Mark Bishton, David Ritchie, et al.
Internal Medicine Journal|September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statementMary A Anderson, Rory Bennett, Xavier Badoux, et al.
NEJM Evidence|June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's LymphomaAngie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Blood Advances|September 8, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA studyStephen Opat, Alessandra Tedeschi, Bei Hu, et al.
Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
Internal Medicine Journal|July 7, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 updateSean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, et al.
Leukemia|April 23, 2022
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphomaJonathan Wong, Emily Gruber, Belinda Maher, et al.
Pageof 14